Nymox

Nymox Pharmaceutical Corporation specializes in the research and development of therapeutics and diagnostics, with a particular emphasis on products addressing unmet needs of the rapidly aging male population in developed economies. The company’s lead candidate for benign prostatic hyperplasia (BPH), Fexapotide Triflutate (FT), has completed Phase 3 development across more than 70 clinical centers in the United States, involving over 1,700 patients throughout the clinical development program. Nymox is now preparing to file for approval in major global economies, including the United States and Europe.